Recent News
Feb 2, 2023
Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference

South San Francisco, CA, February 2, 2023 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...

Dec 20, 2022
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update

South San Francisco, CA, December 20, 2022 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...

Stock Info
NASDAQSTSA